All posts related to "patient input"

Call for patient input on ixekizumab (Taltz) for the treatment of psoriatic arthritis

Stickman with megaphone calling for patient inputDo you have psoriatic arthritis? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for ixekizumab (Taltz) for the treatment of psoriatic arthritis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Let BC PharmaCare hear “Your Voice” on tocilizumab (Actemra™) 

Stick Man figure holding MegaphoneBC PharmaCare is looking for your input on tocilizumab (Actemra™) for the treatment of giant cell arteritis

Tocilizumab (Actemra®) for giant cell arteritis (GCA) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about tocilizumab for the treatment of GCA.

You can give input if you are a B.C. resident and have giant cell arteritis, a caregiver to someone with giant cell arteritis, or if your group represents people who live with giant cell arteritis.

If you would like our help in providing your input, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient organization on your behalf. Please provide your input to us by Monday, February 19 so that we may submit the questionnaire in time for the deadline.

The submission deadline is midnight on February 21, 2018. Patients and caregivers may give their input directly through the links below.

Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:

  • To view the information sheet for tocilizumab for giant cell arteritis: click here
  • For the Patient Questionnaire: click here
  • For the Caregiver Questionnaire: click here
  • For the Patient Group Questionnaire: click here (Patient groups are required to register their name with the Ministry of Health before making their submission.)

Call for patient input on brodalumab for moderate to severe plaque psoriasis

Stickman with megaphone calling for patient inputDo you have moderate to severe plaque psoriasis? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for brodalumab for moderate to severe plaque psoriasis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Call for patient input on tocilizumab (Actemra®) for giant cell arteritis

Stickman with megaphone calling for patient inputCall for patient input on tocilizumab (Actemra®) for giant cell arteritis

Do you have giant cell arteritis? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for tocilizumab (Actemra®) for the treatment of giant cell arteritis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Do you have rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis?

Stickman with megaphone calling for patient inputCall for patient input on biosimilar infliximab (Merck) for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis

Do you have rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis? We need your valuable input

Health Canada defines biosimilars as biologic medicines that are similar to, and would enter the market after, an approved originator biologic (such as Remicade®).

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for biosimilar infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The originator biologic, or reference product, is infliximab (Remicade®).

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Call for patient input on guselkumab for moderate to severe plaque psoriasis

Stickman with megaphone calling for patient inputDo you have moderate to severe plaque psoriasis or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for guselkumab for the treatment of moderate to severe plaque psoriasis.

Guselkumab belongs to the biologic response modifier class of inflammatory arthritis medications. It works by blocking the interleukin (IL)-23 molecule, a cytokine that plays a key role in plaque psoriasis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about public reimbursement of medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Let BC PharmaCare hear “Your Voice” on sarilumab

Stickman with megaphone calling for Your Voice patient inputBC PharmaCare is looking for your input on sarilumab for the treatment of rheumatoid arthritis

Sarilumab (Kevzara™) is a fully human monoclonal antibody that targets IL-6, a protein central to the development of the signs and symptoms of rheumatoid arthritis. Sarilumab can be used alone or in combination with methotrexate or other traditional disease-modifying antirheumatic drugs (DMARDs). It is given by subcutaneous (under the skin) injection. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program.  Continue reading

Call for patient input on biosimilar etanercept (Sandoz) for RA, AS, and pJIA

Stickman with megaphone calling for patient inputDo you have rheumatoid arthritis, ankylosing spondylitis or polyarticular juvenile idiopathic arthritis or care for someone who does? We need your valuable input.

Health Canada defines biosimilars (sometimes referred to as subsequent entry biologics or SEBs) as biologic medicines that are similar to, and would enter the market after, an approved originator biologic (such as Enbrel®).

Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and are sensitive to changes in manufacturing practices. Biosimilars are not identical to their originator products because their chemical characteristics cannot be precisely duplicated during the manufacturing process. Therefore, biosimilars may have unique efficacy, immunogenicity, and safety profiles that are different from their originator.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for biosimilar etanercept for the treatment of rheumatoid arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis. The originator biologic, or reference product, is etanercept (Enbrel®).
Continue reading

Call for patient input on treatment for rheumatoid arthritis

Megaphone GraphicDo you have rheumatoid arthritis or care for someone who does? We want your valuable input

The Common Drug Review (CDR) is welcoming input on the manufacturer’s submission of sarilumab for the treatment of rheumatoid arthritis (RA) from patients and their caregivers.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Let BC PharmaCare hear “Your Voice” on etanercept SEB

Stick man holding megaphoneBC PharmaCare is looking for your input on etanercept SEB for the treatment of rheumatoid arthritis and ankylosing spondylitis

Etanercept SEB is a subsequent entry biologic version of etanercept (Enbrel). Etanercept SEB is used for treating people with moderate to severe rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and works by targeting the tumor necrosis factor alpha (TNFA) molecule. It is given by subcutaneous injection.

A SEB needs to have the same mechanism of action as the originator biologic it was compared to, which means it should work in a similar way. Health Canada defines SEBs as a “biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug.” Continue reading